LION BIOTECHNOLOGIES, INC. (NASDAQ:LBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On May 22, 2017, Greg Schiffman, the Chief Financial Officer of Lion Biotechnologies, Inc. (the “Company”), provided the Company with written notice under his Employment Agreement, dated September 28, 2016, that he would resign from the Company, effective June 22, 2017, for personal reasons.
About LION BIOTECHNOLOGIES, INC. (NASDAQ:LBIO)
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. The Company develops a portfolio of TIL-based products for the treatment of solid tumors. In addition to LN-144, the Company intends to develop additional TIL-based pipeline products to treat a range of solid tumors. It develops LN-145 to treat cervical and head and neck cancers. TIL therapy involves growing a patient’s TIL in special culture conditions outside the patient’s body, or ex vivo, and then infusing the T cells back into the patient in combination with interleukin-2 (IL-2). LION BIOTECHNOLOGIES, INC. (NASDAQ:LBIO) Recent Trading Information
LION BIOTECHNOLOGIES, INC. (NASDAQ:LBIO) closed its last trading session down -0.35 at 6.15 with 282,079 shares trading hands.